DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
Sertraline Hydrochloride is a drug marketed by Aci Healthcare Ltd, Aurobindo Pharma, Ranbaxy Labs Ltd, Accord Hlthcare, Anda Repository, Austarpharma Llc, Cadila, Chartwell Molecular, Fosun Pharma, Heritage Pharma, Hikma Pharms, Invagen Pharms, Ivax Sub Teva Pharms, Lupin, Mylan, Mylan Pharms Inc, Oxford Pharms, Sciegen Pharms Inc, Sun Pharm Inds (in), Sun Pharm Inds Ltd, Torrent Pharms, Viwit Pharm, and Wockhardt. and is included in twenty-nine NDAs.
The generic ingredient in SERTRALINE HYDROCHLORIDE is sertraline hydrochloride. There are twenty-two drug master file entries for this compound. Thirty-nine suppliers are listed for this compound. Additional details are available on the sertraline hydrochloride profile page.
A generic version of SERTRALINE HYDROCHLORIDE was approved as sertraline hydrochloride by AUROBINDO PHARMA on February 6th, 2007.
Recent Clinical Trials for SERTRALINE HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
|University of Texas Southwestern Medical Center||Phase 3|
|Alto Neuroscience||Phase 4|
|Fundação de Amparo à Pesquisa do Estado de São Paulo||Phase 2|